μ opioid receptor:: role for the amino terminus as a determinant of ligand binding affinity

被引:45
作者
Chaturvedi, K [1 ]
Shahrestanifar, M [1 ]
Howells, RD [1 ]
机构
[1] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA
来源
MOLECULAR BRAIN RESEARCH | 2000年 / 76卷 / 01期
关键词
morphine; methadone; endomorphin; fentanyl; opioid receptor;
D O I
10.1016/S0169-328X(99)00332-0
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The importance of the amino-terminal domain of the mu opioid receptor (MOR) as a component of the high affinity ligand-binding pocket was evaluated. A deletion mutant lacking 64 amino acids from the amino-terminus of MOR (Delta N64) was constructed and expressed in HEK 293 cells. The affinities of bremazocine and cyclazocine were similar for the truncated and full-length MORs. Affinities of the mu receptor antagonist, naloxone, and the mu receptor agonist, morphine, were decreased 3.5-fold and 6-fold, respectively, for the truncated receptor relative to the wild-type MOR. Similarly, the affinities of the opioid peptide agonists, DAMGO (Tyr-D-Ala-Gly-MePhe-Gly-ol), beta-endorphin, and DADL (Tyr-D-Ala-Gly-Phe-D-Leu), for the Delta N64 receptor were decreased from 3- to 8-fold as a result of the deletion. In contrast, the affinities of the alkaloid agonists, methadone and fentanyl, and the peptide agonists. endomorphin 1 and endomorphin 3-, for the truncated receptor relative to MOR were reduced dramatically by 20- to 60-fold. MOR is glycosylated when expressed in HEK 293 cells; however, analysis of N-glycosidase F-treated membranes indicated that N-glycan chains within the amino-terminal domain of MOR do not contribute significantly to ligand affinities. These results indicate that amino acid residues within the amino-terminal domain of MOR play a crucial role in the composition of the binding pocket for a select group of agonists. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:64 / 72
页数:9
相关论文
共 55 条
[1]   Role of aromatic transmembrane residues of the delta-opioid receptor in ligand recognition [J].
Befort, K ;
Tabbara, L ;
Kling, D ;
Maigret, B ;
Kieffer, BL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (17) :10161-10168
[2]  
Befort K, 1996, MOL PHARMACOL, V49, P216
[3]   Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity [J].
Blanpain, C ;
Lee, B ;
Vakili, J ;
Doranz, BJ ;
Govaerts, C ;
Migeotte, I ;
Sharron, M ;
Dupriez, V ;
Vassart, G ;
Doms, RW ;
Parmentier, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (27) :18902-18908
[4]  
Bot G, 1998, J NEUROCHEM, V70, P358
[5]   G(0) MEDIATES THE COUPLING OF THE MU-OPIOID RECEPTOR TO ADENYLYL CYCLASE IN CLONED NEURAL CELLS AND BRAIN [J].
CARTER, BD ;
MEDZIHRADSKY, F .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (09) :4062-4066
[6]  
CHEN Y, 1993, MOL PHARMACOL, V44, P8
[7]   Mutation of a conserved serine in TM4 of opioid receptors confers full agonistic properties to classical antagonists [J].
Claude, PA ;
Wotta, DR ;
Zhang, XH ;
Prather, PL ;
McGinn, TM ;
Erickson, LJ ;
Loh, HH ;
Law, PY .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (12) :5715-5719
[8]   Identification of an interaction between residue 6 of the natural peptide ligand and a distinct residue within the amino-terminal tail of the secretin receptor [J].
Dong, MQ ;
Wang, Y ;
Hadac, EM ;
Pinon, DI ;
Holicky, E ;
Miller, LJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (27) :19161-19167
[9]   CLONING OF A DELTA OPIOID RECEPTOR BY FUNCTIONAL EXPRESSION [J].
EVANS, CJ ;
KEITH, DE ;
MORRISON, H ;
MAGENDZO, K ;
EDWARDS, RH .
SCIENCE, 1992, 258 (5090) :1952-1955
[10]   PRIMARY STRUCTURES AND EXPRESSION FROM CDNAS OF RAT OPIOID RECEPTOR DELTA-SUBTYPES AND MU-SUBTYPES [J].
FUKUDA, K ;
KATO, S ;
MORI, K ;
NISHI, M ;
TAKESHIMA, H .
FEBS LETTERS, 1993, 327 (03) :311-314